Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Luyao, Yang, Zongxing, Guo, Fucheng, Chen, Yurong, Wei, Jiarui, Dai, Xiangpeng, Zhang, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351040/
https://www.ncbi.nlm.nih.gov/pubmed/37465684
http://dx.doi.org/10.3389/fimmu.2023.1227797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351040/
https://www.ncbi.nlm.nih.gov/pubmed/37465684
http://dx.doi.org/10.3389/fimmu.2023.1227797

Ejemplares similares